Abstract: A system for managing communication between a vehicle and a broker module includes a telematics unit connected to the vehicle. The telematics unit is configured to carry out wireless data communications according to a publish-subscribe messaging protocol. A command unit is in communication with the telematics unit, the command unit having a processor and tangible, non-transitory memory on which instructions are recorded. The telematics unit is configured to establish a network connection with the broker module. The command unit is adapted to create a dynamic retry delay process for the network connection by varying a connection retry delay time based on a plurality of failure categories and an operation mode of the vehicle. The plurality of failure categories each corresponds to a respective failure in the network connection.

Abstract: Described embodiments provide systems and methods for performing cancer whole genome and transcriptome sequencing (cWGTS). A plurality of datasets can be generated based on sequencing of a tumor sample and a healthy control germline sample. A plurality of databases, comprising a first, second and third database, can be accessed. An RNA gene expression analysis can be performed to generate a first plurality of outputs. A DNA ploidy and allelic imbalance analysis can be performed to generate a second plurality of outputs. A variant calling analysis can be performed to generate a third plurality of outputs. A workflow may be implemented. Cohort classification scores and disease-specific classification scores for each individual level output in each of the first, second, and third pluralities of outputs can be generated. A report can be generated and provided to one or more users.

Abstract: The present disclosure is directed to managing and accessing experiment data. A data processing system may generate a system identifier for each instance that leads to a generation of experiment data. A first segment may refer to a source entity, and may be used to differentiate identifiers generated by different source entities. This implementation may aim to provide an explicit representation of the data generation process while providing a glimpse on select metadata attributes, such as an individual species, sample class, and experimental technique used to generate the dataset. These constraints may prevent duplicates and may enable system-side associations among subjects, samples, aliquots, and experiments.

Abstract: The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

Abstract: The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

Abstract: The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

Abstract: The invention provides compounds and methods of their use in the detection of apoptosis and necrosis both in vitro and in vivo. Also provided are compounds and methods of their use in selective delivery of agents to cells undergoing apoptosis or necrosis. The compounds and methods are based on conjugates formed with a dehydrogenase such as lactate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, and malate dehydrogenase. The compounds and methods are useful in the diagnosis and treatment of conditions characterized by apoptosis, including cancer, cardiac disease, neurologic disease including stroke, and autoimmunity. The compounds and methods offer distinct advantages over corresponding compounds and methods based on Annexin V. Also provided are methods for screening for compounds that modulate, i.e., inhibit or promote, apoptosis.

Abstract: The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

Abstract: The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

Abstract: The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phosphospecific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.

Abstract: The invention methods using a insulin-like growth factor receptor inhibitor to inhibit tumor cell growth in a subject in need thereof.

Abstract: The present invention features a method for determining the prognosis for survival of a cancer patient. Methods for measuring the level of NOL3 expression in a cancer cell-containing sample from a patient, and comparing the level of NOL3 expression in the sample to a reference level of NOL3 expression are also included. A higher level of NOL3 relative to the reference level correlates with decreased survival of the patient, and an equivalent or lower level of NOL3 relative to the reference level correlates with increased survival of the patient.

Abstract: The invention provides compounds and methods of their use in the detection of apoptosis and necrosis both in vitro and in vivo. Also provided are compounds and methods of their use in selective delivery of agents to cells undergoing apoptosis or necrosis. The compounds and methods are based on conjugates formed with a dehydrogenase such as lactate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, and malate dehydrogenase. The compounds and methods are useful in the diagnosis and treatment of conditions characterized by apoptosis, including cancer, cardiac disease, neurologic disease including stroke, and autoimmunity. The compounds and methods offer distinct advantages over corresponding compounds and methods based on Annexin V. Also provided are methods for screening for compounds that modulate, i.e., inhibit or promote, apoptosis.

Abstract: The present invention provides chemokine receptor antibodies that selectively bind to an activated form of the receptor but not to a non activated form of the receptor. In particular, the current invention provides phospho specific chemokine receptor antibodies. The antibodies can be used in several diagnostic, screening and purification methods.

Abstract: The invention methods using a insulin-like growth factor receptor inhibitor to inhibit tumor cell growth in a subject in need thereof.

Abstract: In general, in one aspect, the invention features a method that includes converting radiation at a first wavelength ?i to radiation at a second wavelength ?g and exposing an article to the radiation at ?g to convert the radiation at ?g to radiation at a third wavelength ?r and radiation at a fourth wavelength ?b. ?r is red radiation, ?g is green radiation, and ?b is blue radiation and the article includes lithium tantalate.

Abstract: A tunable coherent light source includes a pump laser for generating a pump beam and an optical parametric oscillator including a crystal exhibiting an output curve for a pump beam of a defined wavelength, the output curve defining wavelengths of signal and idler outputs based on periodically poled grating periods of the crystal. The crystal has a plurality of segments associated with a plurality of grating periods of the output curve, each segment of the plurality of segments having a different crystal structure. At least one of the plurality of segments comprises a crystal structure combining at least two of the grating periods A heating device heats the crystal to an elevated operating temperature and is adjustable for adjusting the output wavelengths of each of the segments.

Abstract: The invention provides methods for identifying compounds that can be used to modify transcriptional responses to hypoxia, and use of such compounds in therapeutic and diagnostic methods.